Adicet to present preclinical data from allogeneic gamma delta t cell platform at sitc 36th annual meeting

Menlo park, calif. and boston, oct. 04, 2021 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta t cell therapies for cancer and other diseases, today announced the company will present data in the form of a poster presentation at the upcoming society for immunotherapy of cancer (sitc) 36th annual meeting to be held november 10-14, 2021.
ACET Ratings Summary
ACET Quant Ranking